Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7965032 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RO7965032 Dose Level 1 | EXPERIMENTAL | Participants will receive RO7965032. |
| RO7965032 Dose Level 2 | EXPERIMENTAL | Participants will receive RO7965032. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo. |
| Name | Type | Description |
|---|---|---|
| RO7965032 | DRUG | RO7965032 will be administered as per the schedule defined in the protocol. |
| Placebo | DRUG | Placebo will be administered as per the schedule defined in the protocol. |
Inclusion Criteria: Ocular Inclusion Criteria for the Study Eye * BCVA score of \>= 35 letters using the ETDRS VA chart at a starting distance of 4 meters * Lesions may be either extrafoveal or subfoveal Ocular Inclusion Criteria for Both Eyes * Sufficiently clear ocular media, adequate pupillar...
RO7965032 is an investigational small molecule being studied for the treatment of geographic atrophy secondary to age-related macular degeneration, an advanced form of dry AMD that causes progressive loss of central vision. It is in Phase 2 clinical development and has not been approved for any use.
RO7965032 is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is running the compound's clinical program in ophthalmology, with geographic atrophy secondary to age-related macular degeneration as the studied indication.
RO7965032 is in Phase 2 clinical development. It is investigational and is being evaluated in a single recruiting Phase 2 study in participants with geographic atrophy secondary to age-related macular degeneration. The program has no completed trials to date.
RO7965032 is being studied in trial NCT07851259, a Phase 2 study assessing its efficacy and safety in participants with geographic atrophy secondary to age-related macular degeneration. The trial is currently recruiting in the United States and is expected to enroll 321 participants aged 50 years and older.
The Phase 2 trial of RO7965032, NCT07851259, is a randomized, double-blind, placebo-controlled study enrolling 321 participants with geographic atrophy secondary to age-related macular degeneration. It accepts participants of all sexes aged 50 years and older and does not enroll healthy volunteers.